We evaluated the use of CD34 þ selected allogeneic peripheral blood as a source of hematopoietic progenitors for allogeneic transplantation in 11 patients with aplastic anemia (AA). The median age was 17 years (range, 6-49), and the median time between diagnosis and transplant 1 month (range, 1-24). Conditioning consisted of cyclophosphamide (50 mg/kg per day) on days À7 to À4 and antithymocyte globulin (30 mg/kg per day) on days À4 to À2 in nine patients. Total lymphoid irradiation was added to the preparative regimen for two. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine A and prednisone. Median doses of CD34 þ and CD3 þ cells infused were 3.91 Â 10 6 and 0.3 Â 10 6 /kg, respectively. The median time taken to achieve a neutrophil count 40.5 Â 10 9 /l was 12 days and to recover a platelet count 420 Â 10 9 /l, 13 days. Two patients developed acute GVHD grade I-II and one developed limited chronic GVHD. There were two treatment-related deaths. At a median follow-up of 44 months (range, 4-73), nine patients were alive with sustained and complete engraftment. This is a promising procedure in patients with AA, resulting in a rapid hematopoietic recovery, a low transplant-related mortality, and a low incidence of GVHD.
peripheral blood; CD34 þ selection Allogeneic stem cell transplantation is the treatment of choice for young patients with severe aplastic anemia (AA). Bone marrow and, recently, peripheral blood stem cells have been used for transplantation. Allogeneic transplantation of peripheral blood progenitor cells (allo-PBT) is associated with faster engraftment than that observed following allogeneic bone marrow transplantation (allo-BMT) [1] [2] [3] [4] with a similar incidence of acute graft-versus-host disease (GVHD). 2, 5, 6 However, a major concern with allo-PBT is the high incidence of chronic GVHD. 3, [7] [8] [9] Ex vivo T-cell depletion (TCD) of the graft can effectively prevent GVHD following allo-BMT. 10 The clinical application of TCD in allo-PBT is also of interest, and several studies have addressed the therapeutic value of this procedure in patients with different diagnoses. [11] [12] [13] Despite this, the experience of this procedure in patients with AA is very limited.
14 Thus, we performed TCD by means of CD34 þ positive selection in a series of 11 patients with AA undergoing allo-PBT (allo-PBT/CD34 þ ) from HLA-identical sibling donors at our institution. Although the number of patients is small and the follow-up limited, our data suggest that the allo-PBT/CD34 þ in patients with AA results in rapid engraftment without significant GVHD and with low treatment-related mortality.
Patients and methods

Patient selection
From June 1996 to January 2004, 11 consecutive patients with AA underwent allo-PBT/CD34 þ from HLA-identical sibling donors at our institution. The diagnosis of AA was based on the peripheral blood count and bone marrow findings. Hypocellular bone marrow aspirate and biopsy were observed in every case. Cytogenetic analysis was carried out in three patients, all of whom had a normal karyotype. Transplantation was performed at a median of 1 month (range, 1-24) after diagnosis. The median patient age was 17 years (range, 5-49). Detailed written informed consent was obtained from each donor and patient before the start of the procedure. With minors, informed consent was provided by their guardians. Patient characteristics are shown in Table 1 .
Eight out of the 11 patients received allo-PBT/CD34 þ as a first-line treatment immediately after diagnosis, and three patients had had previous unsuccessful treatment of their AA by immunosuppressive therapy (two cases) or oxymetholone (one case).
Peripheral blood progenitor cell mobilization and collection
Donors received G-CSF at a median dose of 10 mg/kg per day subcutaneously for 4-5 days. On day 5 (eight cases), and days 5 and 6 (three cases) donors underwent leukapheresis using a continuous cell separator.
Positive selection of CD34 þ cells
In three cases, the first apheresis product was stored at 41C overnight without shaking and pooled the next day with the second apheresis product. CD34 þ cells were then positively selected using a biotin-avidin immunoadsorption column (Ceprate SC System; CellPro, Bothell, WA, USA) in three cases, or using CliniMACS (Miltenyi Biotec, Bergisch Gladbach, Germany) in the remaining eight cases. In the latter cases, the median number of CD3 þ cells remaining in the graft after the CD34 þ selection procedure was o1 Â 10 4 /kg. In these cases, and to achieve similar quantities of T cells to those infused following the avidin-biotin immunoadsorption column selection, additional CD3 þ cells were added to the CD34 þ selected product. CD3 þ cells were added to achieve a final number of 0.3 Â 10 6 /kg T cells in the graft. T cells were not administered after transplant in any case. CD34 þ and CD3 þ cells were quantified as previously reported. 15 The CD34 þ positive fraction was infused to patients, without previous cryopreservation, as the sole source of progenitor cells in every case. The median number of CD34 þ cells and CD3 þ cells infused to the patients was 3.91 Â 10 6 /kg (range, 1.7-11.39) and 0.3 Â 10 6 /kg (range, 0.1-0.7), respectively.
Conditioning regimen
The conditioning regimen consisted of cyclophosphamide (50 mg/kg per day) on days À7 to À4 and antithymocyte globulin (ATG) (30 mg/kg per day) on days À4 to À2 in nine patients. In the remaining two, total lymphoid irradiation (5 Gy) was added to the preparative regimen. The first day of CD34 þ selected infusion was considered as day 0.
Supportive care and GVHD prophylaxis
Post transplant supportive care was in accordance with center guidelines. G-CSF was administered at a daily dose of 5 mg/kg per day from day þ 7 until neutrophil engraftment. GVHD prophylaxis consisted of cyclosporine A (CsA) plus steroids. CsA was started at 1.5 mg/kg intravenously every 12 h from day -1 and adjusted to maintain therapeutic blood levels of 250-400 ng/ml. Methylprednisolone was administered at a daily dose of 0.5 mg/kg per day on days þ 7 to þ 14, increased to1 mg/kg per day on days þ 15 to þ 28 and then tapered off. CsA dose was reduced if renal function decreased, regardless of blood concentrations. CsA was given orally as soon as oral mucositis disappeared and was stopped by day 180 after transplantation.
Definitions
Time to neutrophil engraftment was considered as the first of three consecutive days with an absolute neutrophil count (ANC) 40.5 Â 10 9 /l. Time to platelet engraftment was assessed by determining the number of days after day 0 required to maintain an untransfused platelet count 420 Â 10 9 /l. Chimerism status was assessed in peripheral blood by means of VNTR or STR in six out of 11 patients starting one month after transplant. 16 The diagnosis and grading of acute and chronic GVHD were established according to Seattle criteria. 17 Chronic GVHD was defined if it was present after day 100. Skin biopsies were taken from all patients with skin rashes. Regimen-related toxicity (RRT) was graded using Bearman criteria. 18 Transplant-related mortality was defined as death from causes other than relapse.
Results
Engraftment and GVHD
One patient died on day þ 2 and was not evaluable for engraftment. Overall, the median time taken to achieve a neutrophil count 40.5 Â 10 9 /l for the 10 remaining patients was 12 days (range, 9-13), and the median time to recover an untransfused platelet count 420 Â 10 9 /l was 13 days (range, . Six out of the nine long-term survivors with information available had complete and sustained donor chimerism at last follow-up, and no patient developed late graft failure. Complete blood counts at diagnosis and at last follow-up are shown in Table 2 .
Two patients developed acute GVHD clinical grade I-II (skin) responsive to treatment. In no case was acute GVHD grade III or IV observed. The median follow-up of the nine patients eligible for chronic GVHD evaluation was 44 months (range, 4-73). Only one patient developed limited chronic GVHD responsive to steroid therapy on day 300 after transplant, which was promptly arrested without GVHD reactivation.
Transplant-related complications
Mild or moderate mucositis was the toxicity most frequently seen. Severe mucositis was not observed. Every patient presented with fever. Infection was clinically documented in three patients and was considered of unknown origin in the remaining eight. Cytomegalovirus (CMV) reactivation was observed in two patients, and was managed with ganciclovir (5 mg/kg per 12 h for 15 days). No patient developed CMV disease. There were two treatment-related deaths. One patient presented with bacterial pneumonia during conditioning therapy, required mechanical respiratory support, and died on day þ 2. The remaining patient presented with severe respiratory insufficiency that required mechanical respiratory support because of a pulmonary hemorrhage on day 0. He subsequently developed a cerebral hemorrhage and died on day þ 21. The remaining nine patients are alive with a median follow-up of 1418 days (range, 128-1854) and a Karnofsky status of 90-100%.
Discussion
This study shows that allo-PBT/CD34 þ in patients with AA is a safe procedure, associated with an acceptable rate of transplant-related mortality, rapid engraftment, and a low incidence of GVHD.
Two patients in our series died due to treatment-related complications. Although the mortality is slightly higher than that observed after allogeneic bone marrow transplantation (allo-BMT), 19 it should be highlighted that in both cases the death was related to serious complications which developed during the conditioning period (bacterial pneumonia and cerebral hemorrhage) and which were not directly related to the source of stem cells used for transplantation.
Graft failure is one of the most severe complications occurring after allo-SCT. The speed of engraftment seen here was similar to that observed in patients transplanted with unmodified allo-PBT. [2] [3] [4] Remarkably, engraftment occurred in all patients, and none had late graft rejection. Engraftment failure occurs in 5-25% of patients with AA using bone marrow from HLA-identical siblings, [19] [20] [21] [22] and is frequently observed in recipients of TCD marrow. [23] [24] [25] Several studies have shown, however, that 'partial' TCD is associated with a lower risk of graft failure than 'total' TCD. 26, 27 In our study, every patient received a T-cell dose of 40.1 Â 10 6 /kg in the graft, and this is in sharp contrast to data from other studies using totally TCD grafts which report graft failure rates of up to 15%. 28 In this regard, although the optimum number of T cells that should be left in the graft to allow reliable engraftment is presently unknown, our series supports the idea that the number of CD3 þ cells in the inoculum is the most critical factor relating to the development of graft failure after allo-PBT/ CD34 þ , as has been recently suggested. 27, 29 Acute GVHD, grade I or II, was observed in two patients, but was limited to the skin. When compared with the data reported by other groups after standard allo-BMT, 19 no patient in our series developed grade III or IV acute GVHD. In this regard, the detrimental effect played by grade II-IV acute GVHD on the outcome of patients with AA given an allograft is well known. 30 Thus, this low incidence of severe acute GVHD after allo-PBT/CD34 þ can be an additional advantage in patients with AA undergoing transplantation.
Two patients received total lymphoid irradiation in the conditioning regimen. However, due to the higher risk of CD34 þ selected transplantation for aplastic anaemia J de la Rubia et al long-term complications in these patients, 31 ,32 irradiation was not used in the conditioning regimen of the remaining cases.
TCD of the graft is the most effective method of decreasing chronic GVHD. 10, 33 In our study, chronic GVHD was observed in only one patient and was limited to the skin, an incidence well below that generally observed after unmodified allo-PB transplantation, 3, [7] [8] [9] and also lower than that observed after allo-BMT for AA. 19, 22 This low incidence of chronic GVHD is probably because allo-PBT/CD34 þ prevents severe acute GVHD, the major risk for chronic GVHD. 34 As a result of TCD of the allograft, there is a low recovery of CD4 þ lymphocytes during the first 6 months after the transplant, which can be related to a high probability of severe infections, 35 although this has not been confirmed by others. 36 We did not perform serial studies of lymphocyte recovery after transplantation in this series. However, no patient developed a severe infection after transplant requiring hospitalization, suggesting that delayed immune recovery in this setting is of minor clinical significance.
One concern with TCD of the allograft is the potential increase in CMV infections caused by elimination of CMVspecific mature T-cell clones from the graft, which confer immunity to the virus during the first months after transplantation. 37, 38 However, in this study, CMV reactivation was rare, and no patient developed CMV disease. In this regard, GVHD is also an important risk factor for developing CMV infections and disease. 39, 40 As already mentioned, in our series no severe GVHD was observed, suggesting that partial TCD in allo-PBT will exploit the advantages of peripheral blood as a source of hematopoietic progenitors without significantly increasing the risk of serious viral infections.
To summarize, although the number of patients is too small to draw definitive conclusions, our results suggest that allo-PBT/CD34 þ from HLA-identical sibling donors is a valid source for stem cell transplantation in patients with AA. Our results also suggest that the procedure is associated with rapid hematopoietic recovery after the transplantation, a low transplant-related mortality, and a low incidence of GVHD.
